Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Hypertension Reports
Published in: Current Hypertension Reports 3/2015

01-03-2015 | Hypertension and Metabolic Syndrome (JR Sowers and A Whaley-Connell, Section Editors)

Natriuretic Peptides as a Novel Target in Resistant Hypertension

Authors: Pratik Patel, Horng H. Chen

Published in: Current Hypertension Reports | Issue 3/2015

Login to get access

Abstract

Resistant hypertension is defined as blood pressure not under goal despite being on at least three antihypertensives. Resistant hypertension is associated with significant cardiovascular morbidity and mortality. Currently, the mainstay for the treatment of resistant hypertension is lifestyle modification and antihypertensive drugs. Natriuretic peptides play an important role in regulating cardiovascular hemodynamics and sodium and fluid homeostasis including blood pressure control. They hold a promising potential for treatment of resistant hypertension.
Literature
1.
Calhoun DA et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for high blood pressure research. Hypertension. 2008;51(6):1403–19.CrossRefPubMed
2.
Cushman WC et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens. 2002;4(6):393–404.CrossRef
3.••
Tanner RM et al. Prevalence of apparent treatment-resistant hypertension among individuals with CKD. Clin J Am Soc Nephrol CJASN. 2013;8(9):1583–90. This study describes the prevalence of resistant hypertension in patients with chronic kidney disease.CrossRef
4.•
Persell SD. Prevalence of resistant hypertension in the United States, 2003–2008. Hypertension. 2011;57(6):1076–80. This study describes the prevalence of resistant hypertension in large U.S. population.CrossRefPubMed
5.••
Egan BM et al. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation. 2011;124(9):1046–58. This study describes the prevalence of resistant hypertension a diverse U.S. population.CrossRefPubMedCentralPubMed
6.•
7.
Weinberger MH et al. Dietary sodium restriction as adjunctive treatment of hypertension. JAMA. 1988;259(17):2561–5.CrossRefPubMed
8.
Henningsen NC et al. Hypertension, levels of serum gamma glutamyl transpeptidase and degree of blood pressure control in middle-aged males. Acta Med Scand. 1980;207(4):245–51.PubMed
9.
Lloyd-Jones DM et al. Differential control of systolic and diastolic blood pressure: factors associated with lack of blood pressure control in the community. Hypertension. 2000;36(4):594–9.CrossRefPubMed
10.
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981–97.
11.
Ho H et al. Association between the CYP3A5 genotype and blood pressure. Hypertension. 2005;45(2):294–8.CrossRefPubMed
12.
Vongpatanasin W. Resistant hypertension: a review of diagnosis and management. JAMA. 2014;311(21):2216–24.CrossRefPubMed
13.
Gupta AK et al. Baseline predictors of resistant hypertension in the Anglo-Scandinavian cardiac outcome trial (ASCOT): a risk score to identify those at high-risk. J Hypertens. 2011;29(10):2004–13.CrossRefPubMed
14.
de Haro Moraes C et al. High-circulating leptin levels are associated with increased blood pressure in uncontrolled resistant hypertension. J Hum Hypertens. 2013;27(4):225–30.CrossRefPubMed
15.
Papademetriou V et al. Renal nerve ablation for resistant hypertension: how did we get here, present status, and future directions. Circulation. 2014;129(13):1440–51.CrossRefPubMed
16.
17.
Gaddam KK et al. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med. 2008;168(11):1159–64.CrossRefPubMedCentralPubMed
18.
De Nicola L et al. Prevalence and prognostic role of resistant hypertension in chronic kidney disease patients. J Am Coll Cardiol. 2013;61(24):2461–7.CrossRefPubMed
19.
Taler SJ, Textor SC, Augustine JE. Resistant hypertension: comparing hemodynamic management to specialist care. Hypertension. 2002;39(5):982–8.CrossRefPubMed
20.
Garg JP et al. Resistant hypertension revisited: a comparison of two university-based cohorts. Am J Hypertens. 2005;18(5 Pt 1):619–26.CrossRefPubMed
21.
Materson BJ et al. Results of combination anti-hypertensive therapy after failure of each of the components. Department of Veterans Affairs Cooperative Study Group on Anti-hypertensive Agents. Journal of human hypertension, 1995. 9(10): p. 791–6.
22.
Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens. 2003;16(11 Pt 1):925–30.CrossRefPubMed
23.
Cody RJ et al. Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. J Clin Invest. 1986;78(5):1362–74.CrossRefPubMedCentralPubMed
24.
Burnett Jr JC, Granger JP, Opgenorth TJ. Effects of synthetic atrial natriuretic factor on renal function and renin release. Am J Physiol. 1984;247(5):F863–6.PubMed
25.
Schirger JA et al. Vascular actions of brain natriuretic peptide: modulation by atherosclerosis and neutral endopeptidase inhibition. J Am Coll Cardiol. 2000;35(3):796–801.CrossRefPubMed
26.
Brunner-La Rocca HP et al. Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects. J Am Coll Cardiol. 2001;37(5):1221–7.CrossRefPubMed
27.
Yamamoto K, Burnett Jr JC, Redfield MM. Effect of endogenous natriuretic peptide system on ventricular and coronary function in failing heart. Am J Physiol. 1997;273(5 Pt 2):H2406–14.PubMed
28.
Kasama S et al. Effect of atrial natriuretic peptide on left ventricular remodelling in patients with acute myocardial infarction. Eur Heart J. 2008;29(12):1485–94.CrossRefPubMed
29.
Tsuruda T et al. Brain natriuretic peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ Res. 2002;91(12):1127–34.CrossRefPubMed
30.•
Kario K et al. Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study. Hypertension. 2014;63(4):698–705. This study showed that LCZ696 led to better blood pressure control in Asian patients compared with an ARB.CrossRefPubMed
31.
Kinnunen P, Vuolteenaho O, Ruskoaho H. Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: effect of stretching. Endocrinology. 1993;132(5):1961–70.PubMed
32.
Rubattu S et al. NPR-C: a component of the natriuretic peptide family with implications in human diseases. J Mol Med. 2010;88(9):889–97.CrossRefPubMed
33.
Chen HH, Burnett Jr JC. C-type natriuretic peptide: the endothelial component of the natriuretic peptide system. J Cardiovasc Pharmacol. 1998;32 Suppl 3:S22–8.PubMed
34.
Gaspari TA et al. Type-C natriuretic peptide prevents development of experimental atherosclerosis in rabbits. Clin Exp Pharmacol Physiol. 2000;27(8):653–5.CrossRefPubMed
35.
Anand-Srivastava MB. Natriuretic peptide receptor-C signaling and regulation. Peptides. 2005;26(6):1044–59.CrossRefPubMed
36.
Kenny AJ, Bourne A, Ingram J. Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11. Biochem J. 1993;291(1):83–8.PubMedCentralPubMed
37.
Forssmann W, Meyer M, Forssmann K. The renal urodilatin system: clinical implications. Cardiovasc Res. 2001;51(3):450–62.CrossRefPubMed
38.
Lisy O et al. Therapeutic actions of a new synthetic vasoactive and natriuretic peptide, dendroaspis natriuretic peptide, in experimental severe congestive heart failure. Hypertension. 2001;37(4):1089–94.CrossRefPubMed
39.
40.
41.•
McKie PM, Ichiki T, Burnett Jr JC. M-atrial natriuretic peptide: a novel antihypertensive protein therapy. Curr Hypertens Rep. 2012;14(1):62–9. This review paper describes MNAP, a novel ANP-based peptide and its potential for a novel agent to treat hypertension.CrossRefPubMed
42.
Newton-Cheh C et al. Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. Nat Genet. 2009;41(3):348–53.CrossRefPubMedCentralPubMed
43.
Steinhelper ME, Cochrane KL, Field LJ. Hypotension in transgenic mice expressing atrial natriuretic factor fusion genes. Hypertension. 1990;16(3):301–7.CrossRefPubMed
44.
John SW et al. Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension. Science. 1995;267(5198):679–81.CrossRefPubMed
45.
Campese VM et al. Salt intake and plasma atrial natriuretic peptide and nitric oxide in hypertension. Hypertension. 1996;28(3):335–40.CrossRefPubMed
46.
Macheret F et al. Human hypertension is characterized by a lack of activation of the antihypertensive cardiac hormones ANP and BNP. J Am Coll Cardiol. 2012;60(16):1558–65.CrossRefPubMedCentralPubMed
47.
Xue H et al. Atrial natriuretic peptide gene promoter polymorphism is associated with left ventricular hypertrophy in hypertension. Clin Sci. 2008;114(2):131–7.CrossRefPubMed
48.
Knappe S et al. Functional analysis of the transmembrane domain and activation cleavage of human corin: design and characterization of a soluble corin. J Biol Chem. 2003;278(52):52363–70.CrossRefPubMed
49.
Dries DL et al. Corin gene minor allele defined by 2 missense mutations is common in blacks and associated with high blood pressure and hypertension. Circulation. 2005;112(16):2403–10.CrossRefPubMed
50.
Suwa M et al. Multicenter prospective investigation on efficacy and safety of carperitide for acute heart failure in the ‘real world’ of therapy. Circ J Off J Japan Circ Soc. 2005;69(3):283–90.
51.
Colucci WS et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med. 2000;343(4):246–53.CrossRefPubMed
52.
Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA, 2002. 287(12): p. 1531–40.
53.•
Williams B et al. Rationale and study design of the prospective comparison of angiotensin receptor neprilysin inhibitor with angiotensin receptor blocker MEasuring arterial sTiffness in the eldERly (PARAMETER) study. BMJ Open. 2014;4(2):e004254.CrossRefPubMedCentralPubMed
54.
Lee CY et al. Pharmacodynamics of a novel designer natriuretic peptide, CD-NP, in a first-in-human clinical trial in healthy subjects. J Clin Pharmacol. 2009;49(6):668–73.CrossRefPubMedCentralPubMed
55.
Kousholt BS. Natriuretic peptides as therapy in cardiac ischaemia/reperfusion. Dan Med J. 2012;59(6):B4469.PubMed
56.
Therrien JP et al. A gene therapy approach for long-term normalization of blood pressure in hypertensive mice by ANP-secreting human skin grafts. Proc Natl Acad Sci U S A. 2010;107(3):1178–83.CrossRefPubMedCentralPubMed
57.
McKie PM et al. A human atrial natriuretic peptide gene mutation reveals a novel peptide with enhanced blood pressure-lowering, renal-enhancing, and aldosterone-suppressing actions. J Am Coll Cardiol. 2009;54(11):1024–32.CrossRefPubMedCentralPubMed
58.
McKie PM et al. A novel atrial natriuretic peptide based therapeutic in experimental angiotensin II mediated acute hypertension. Hypertension. 2010;56(6):1152–9.CrossRefPubMed
59.••
McKie PM et al. M-atrial natriuretic peptide and nitroglycerin in a canine model of experimental acute hypertensive heart failure: differential actions of 2 cGMP activating therapeutics. J Am Heart Assoc. 2014;3(1):e000206. This in vivo study of a canine model of hypertensive heart failure showed M-ANP administration led to reduction in mean arterial pressure. CrossRefPubMedCentralPubMed
60.
Lazzeri C et al. Systemic hemodynamics and renal function during brain natriuretic peptide infusion in patients with essential hypertension. Am J Hypertens. 1995;8(8):799–807.CrossRefPubMed
61.
Franco-Saenz R, Somani P, Mulrow PJ. Effect of atrial natriuretic peptide (8-33-Met ANP) in patients with hypertension. Am J Hypertens. 1992;5(5 Pt 1):266–75.PubMed
62.
Singer DR et al. Prolonged decrease in blood pressure after atrial natriuretic peptide infusion in essential hypertension: a new anti-pressor mechanism? Clin Sci. 1989;77(3):253–8.PubMed
63.
Zhang WG et al. Effects of atrial natriuretic factor on patients with renovascular hypertension. Chin Med J. 1992;105(9):732–7.PubMed
64.
Predel HG et al. Atrial natriuretic peptide in patients with essential hypertension. Hemodynamic, renal, and hormonal responses. Am J Hypertens. 1991;4(11):871–9.PubMed
65.
Cusson JR et al. Prolonged low dose infusion of atrial natriuretic factor in essential hypertension. Clin Exp Hypertens Part A Theory Prac. 1990;12(1):111–35.CrossRef
66.
Burnier M et al. Bolus injections of synthetic atrial natriuretic peptide in patients with chronic renal failure or nephrotic syndrome. J Cardiovasc Pharmacol. 1989;13(5):682–90.CrossRefPubMed
67.
Cataliotti A et al. Sustained blood pressure-lowering actions of subcutaneous B-type natriuretic peptide (nesiritide) in a patient with uncontrolled hypertension. Mayo Clin Proc. 2012;87(4):413–5.CrossRefPubMedCentralPubMed
68.
Bevan EG et al. Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension. J Hypertens. 1992;10(7):607–13.CrossRefPubMed
69.
Richards AM et al. Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II. J Hypertens. 1993;11(4):407–16.CrossRefPubMed
70.
Ruilope LM et al. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet. 2010;375(9722):1255–66.CrossRefPubMed
71.
McMurray JJ et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004. This randomized,double blinded, placebo controlled study showed angiotensin receptor -neprilysin inhbitor led to better outcomes compared with ace inhibitor in patients with systolic heart failure.CrossRefPubMed
Metadata
Title
Natriuretic Peptides as a Novel Target in Resistant Hypertension
Authors
Pratik Patel
Horng H. Chen
Publication date
01-03-2015
Publisher
Springer US
Published in
Current Hypertension Reports / Issue 3/2015
Print ISSN: 1522-6417
Electronic ISSN: 1534-3111
DOI
https://doi.org/10.1007/s11906-014-0530-0

Other articles of this Issue 3/2015

Current Hypertension Reports 3/2015 Go to the issue

Pulmonary Hypertension (N Hill, Section Editor)

Metabolic Dysfunction in Pulmonary Arterial Hypertension

Hypertension and Metabolic Syndrome (JR Sowers and A Whaley-Connell, Section Editors)

Visit-to-Visit Variability of Systolic Blood Pressure and Cardiovascular Disease

Hypertension and Metabolic Syndrome (JR Sowers and A Whaley-Connell, Section Editors)

The Western Diet and Chronic Kidney Disease

Secondary Hypertension: Nervous System Mechanisms (J Bisognano, Section Editor)

The Baroreflex in Hypertension

Secondary Hypertension: Nervous System Mechanisms (J Bisognano, Section Editor)

Renal Denervation in Heart Failure

Antihypertensive Agents: Mechanisms of Drug Action (ME Ernst, Section Editor)

Thiazide Diuretics in Chronic Kidney Disease
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits